Estradiol is the primary form of estrogen in premenopausal women, and the most important estrogen for replacement therapy. But estradiol is not a single product — it comes in patches, gels, creams, sprays, vaginal rings, pellets, oral tablets, and injectable forms. Each delivers estradiol to your body in a fundamentally different way, with meaningfully different clinical outcomes.
The choice of delivery method is not trivial. It affects absorption predictability, cardiovascular safety profile, liver metabolism, blood clot risk, and symptom control. Most women receive whatever form their doctor is most comfortable prescribing — often oral tablets — when a transdermal option would be significantly safer and more effective for them.
The Forms and Their Differences
Oral estradiol (tablets) is absorbed through the gut and processed by the liver before reaching systemic circulation — a process called first-pass metabolism. This liver passage increases the production of clotting factors, elevates triglycerides, and raises C-reactive protein (an inflammatory marker). The result is a moderately elevated clot risk compared to transdermal options. Oral estradiol also produces inconsistent blood levels due to variable gut absorption.
Transdermal patches deliver estradiol directly through the skin into the bloodstream, bypassing the liver entirely. This dramatically reduces clot risk and produces more stable blood levels. Multiple studies — including the landmark ESTHER study — show that transdermal estradiol carries no increased venous thromboembolism risk compared to oral estradiol, which does. Patches are changed every 3–4 days and provide predictable dosing.
Transdermal gels and creams share the same liver-bypass advantage as patches. They offer more dosing flexibility — you can titrate the dose more precisely — but require more attention to application, skin transfer risk (to partners or children who contact the application site), and absorption consistency based on skin condition and hydration.
Vaginal estradiol (rings, creams, suppositories) is applied locally and has minimal systemic absorption at low doses. It's primarily used to address genitourinary symptoms — vaginal dryness, atrophy, painful intercourse, urinary urgency — and is not a substitute for systemic HRT in women with significant vasomotor or systemic symptoms.
Subcutaneous pellets are small capsules implanted under the skin, typically in the hip or buttock area. They release estradiol continuously over 3–6 months. Pellets provide very stable blood levels and excellent symptom control, but dosing cannot be adjusted once inserted, and pellets cannot be removed if a patient has an adverse reaction.
Dosing: What Optimal Looks Like
There is no universal optimal dose. Dosing is determined by symptom control and blood levels — not by age or years post-menopause. The goal is to restore estradiol to levels consistent with the premenopausal mid-follicular phase: approximately 50–150 pg/mL serum estradiol.
Common starting doses for transdermal patches are 0.05–0.1 mg/day. For gels, this varies by product. These are starting points — many women require higher doses for adequate symptom control, and the dose should be adjusted based on symptom response and labs, not on physician discomfort with higher doses.
Bioidentical vs. Conventional Estradiol
Bioidentical estradiol has the same molecular structure as the estradiol your body produces. Conventional pharmaceutical estradiol products (Vivelle, Climara, Estrace) are also bioidentical — the term does not belong exclusively to compounded products. The distinction that matters is bioidentical vs. conjugated equine estrogens (Premarin), which contain multiple estrogen compounds not native to the human body.
Compounded bioidentical estradiol allows dose customization beyond what pharmaceutical products offer — which matters for women who respond to doses between standard pharmaceutical formulations, or who require combinations not available in standard products.
Making the Right Choice
For most women, a transdermal patch or gel is the starting point — it offers the best safety profile, predictable absorption, and dose flexibility. Oral estradiol remains appropriate for some women but should be chosen deliberately, not by default.
The right choice depends on your cardiovascular risk factors, your response to different delivery methods, your lifestyle, and your physician's clinical judgment. What it should not depend on is what's most familiar to a generalist who doesn't specialize in hormone optimization.